Curis Lifesciences IPO Last Date, Price, Prospectus PDF
| Get instant news updates: Click here to join our Whatsapp Group |
Curis Lifesciences has released IPO and all details of IPO such as last date to apply, price, prospectus PDF and all other details are given below.
Curis Lifesciences IPO Details
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹120 to ₹128 Per Share |
| Issue Size | Approx ₹27.52 Crores |
| Fresh Issue | Approx ₹27.52 Crores |
| Issue Type | Book Built Issue |
| IPO Listing | NSE SME |
| Download Prospectus PDF | Click Here |
Curis Lifesciences IPO Dates and Schedule
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Basis of Allotment | November 12, 2025 |
| Refunds | November 13, 2025 |
| Credit to Demat Account | November 13, 2025 |
| IPO Listing Date | November 14, 2025 |
| IPO Bidding Cut-off Time | November 11, 2025 – 5 PM |
About Curis Lifesciences IPO
Curis Lifesciences Limited, established in 2010, is a pharmaceutical company engaged in developing, manufacturing, and distributing a wide range of medicines. It produces pharmaceutical products both in India and abroad, either on a loan license or contract basis, and also manufactures products under its own brand name for marketing.
The company works with over 100 corporate clients for loan license or contract manufacturing and serves two clients under its own brand marketing in Yemen and Kenya. Its product range includes general pharmaceutical tablets and capsules, oral liquids, external preparations, and sterile ophthalmic ointments.
Curis Lifesciences operates a modern manufacturing facility in Sanand, Gujarat, which follows strict quality control standards to ensure the safety and effectiveness of its products. As of July 31, 2025, the company had 95 permanent employees.
The company’s strengths include experienced promoters and management, a wide variety of products, a strategically located manufacturing facility, a scalable business model, and a strong focus on quality assurance.
